Hematology-American Society of Hematology Education Program

Papers
(The H4-Index of Hematology-American Society of Hematology Education Program is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Managing toxicities of Bruton tyrosine kinase inhibitors92
Therapeutic development and current uses of BCL-2 inhibition74
Platelet transfusion refractoriness: how do I diagnose and manage?49
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors45
Preventing infections in children and adults with asplenia44
Monoclonal gammopathies of clinical significance42
Gene therapy for hemophilia40
Updates in infection risk and management in acute leukemia40
Bispecifics, trispecifics, and other novel immune treatments in myeloma40
Updates in chronic graft-versus-host disease34
Dyskeratosis congenita and telomere biology disorders34
Therapy for lower-risk MDS34
Management of AL amyloidosis in 202034
Next-generation cell therapies: the emerging role of CAR-NK cells32
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes30
Inferior vena cava filters: a framework for evidence-based use29
Does ABO and RhD matching matter for platelet transfusion?28
Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics27
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia26
“TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry26
Advances in the management of α-thalassemia major: reasons to be optimistic26
Future of CAR T cells in multiple myeloma25
Outpatient transfusions for myelodysplastic syndromes24
Management of Waldenström macroglobulinemia in 202024
Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review24
Modern management of Fanconi anemia24
Approach to the patient with suspected hypereosinophilic syndrome24
0.03336501121521